Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars
Adoption Of Adalimumab Rivals ‘Has Not Reached Anticipated Potential’
Boehringer Ingelheim’s decision not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the wider problems for Humira biosimilars in the US.
